In keeping with our belief of bringing a high level of valuable intelligence to the pharmaceutical community, we are pleased to share a report from our colleagues at BioMedtracker.
The annual J.P. Morgan Healthcare Conference wrapped up earlier this month in San Francisco with a huge gathering of biotech and pharma companies coming together to discuss pipelines, partnerships, and promises for the new year. One notable highlight was the emergence of CAR-T therapies which also made headlines at the annual American Society of Hematology (ASH) meeting held just last month. Companies including Kite Pharma (KITE), bluebird bio (BLUE), and Ziopharm Oncology (ZIOP) presented aggressive plans to develop these cell-based therapies for hematologic cancers, but also for the much larger solid tumor indications. The CAR-T immunotherapy race follows on the heels of the first PD-1 immunotherapy approvals, and at the meeting, Merck (MRK) announced plans to keep that PD-1 landscape competitive with an acceleration of their development timeline for Keytruda for lung cancer. Regeneron (REGN) also entered the PD-1 race with the announcement of an IND filing for REGN2810.
Also in oncology, Clovis (CLVS) provided updates on its exciting NSCLC drug, rociletinib, including plans to evaluate the drug for the larger non-EGFR mutant population. Pharmacyclics (PCYC) also announced plans to develop its hematologic blockbuster, Imbruvica, for solid tumors. Pfizer (PFE) finally provided information on its early-stage asset, PF-06463922 for lung cancer, with the disclosure that a pivotal trial should begin this year.
Outside of oncology, Vertex (VRTX) released additional details on its VX-661 + ivacaftor program including plans to start clinical testing in February. Data from the double combination is expected early this year, and a much anticipated trial with a next-generation corrector added to the combination will also start this year. Pfizer (PFE) announced a potential pivotal study for accelerated approval of its 4-antigen Staphylococcus vaccine would initiate in mid-2015. Finally, ZS Pharma (ZSPH) suggested that its lead asset, ZS-9 for the treatment of hyperkalemia, would be priced in-line with other drugs used to treat electrolyte imbalances in other disorders.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: